PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease

Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease.

Effects of varying COVID-19 vaccination rates on population-level health outcomes across variant waves in the U.S.

January 23, 2024

IQVIA and Propel to hold on deal close as FTC case proceeds

IQVIA’s proposed merger with Propel Media won’t close until at least Nov. 23, as a district court considers the FTC’s request to block the deal,

July 26, 2023

Merck KGaA’s life science unit is still feeling the Covid demand decline

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.